Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A

Pharnext SCA

11/12/2023 07:36

Dec 11 (Reuters) - Pharnext SA  PHARN.PA :
    * PHARNEXT REPORTS TOPLINE RESULTS FROM THE PIVOTAL PHASE
III
CLINICAL TRIAL (PREMIER TRIAL) OF PXT3003 IN CHARCOT-MARIE-TOOTH
DISEASE TYPE 1A
    * OVERALL NEUROPATHY LIMITATION SCALE (ONLS) DID NOT CONFIRM
FINDINGS FROM OUR PREVIOUS CLINICAL TRIAL
    * TRIAL REAFFIRMED THE HIGH SAFETY PROFILE OF THE TREATMENT,
ALREADY ESTABLISHED IN PREVIOUS STUDIES. THIS SAFETY PROFILE IS
CRUCIAL FOR TREATMENTS OF CHRONIC DISEASES SUCH AS CMT1A
    * OTHER DATA FROM TRIAL SUGGEST NO DETERIORATION IN
CONDITION OF
PATIENTS UNDER TREATMENT, WHICH IS A POSITIVE SIGN IN CONTEXT OF
DEGENERATIVE DISEASE SUCH AS CMT1A
    * PLANS TO CONTINUE ANALYZING THE DATA, PARTICULARLY IN
COLLABORATION WITH POTENTIAL PARTNERS FOR LICENSING OR
ACQUISITION OF PXT3003

Source text for Eikon:  ID:nACT83278 
Further company coverage:  PHARN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))